Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors – can we RECIST? Focus on colorectal cancer

Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors – can we RECIST? Focus on colorectal cancer

Interest in the measurement of circulating tumor DNA (ctDNA) in colorectal cancer (CRC) has increased during the past decade. The analysis of quantitative ctDNA changes as a general response evaluation criterion during systemic treatment is a scientific approach with high clinical potential, and res...

Full description

Bibliographic Details
Main Authors:	Karen-Lise Garm Spindler, Anders Jakobsen
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-04-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/17588359231171580

Similar Items

Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients
by: Mayte Delgado-Ureña, et al.
Published: (2018-09-01)

RECIST 1.1 CRITERIA IN THE ASSESSMENT OF LUNG TUMORS
by: O. N. Chernova, et al.
Published: (2017-03-01)

The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization
by: Jae Seung Lee, et al.
Published: (2020-11-01)

Circulating DNA and frequency of colorectal cancer brain metastases in a presumed high-risk group
by: Louise Bach Callesen, et al.
Published: (2023-10-01)

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
by: James L Gulley, et al.
Published: (2022-02-01)

Time for a lead-time definition? Author response to ‘Why the length of recurrence free survival or “lead-times” can be misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis’
by: Karen-Lise Garm Spindler, et al.
Published: (2023-03-01)

Is response evaluation criteria in solid tumors (RECIST) effective in patient selection for radical resection after neoadjuvant immunotherapy with advanced NSCLC?
by: Yuan Xu, et al.
Published: (2023-06-01)

Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations
by: Kai Xiong, et al.
Published: (2024-07-01)

A call for objectivity: Radiologists’ proposed wishlist for response evaluation in solid tumors (RECIST 1.1)
by: Kathleen Ruchalski, et al.
Published: (2024-11-01)

Curative effect assessment of immunotherapy for non‐small cell lung cancer: The “blind area” of Immune Response Evaluation Criteria in Solid Tumors (iRECIST)
by: Peng Song, et al.
Published: (2019-04-01)

Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy
by: Cory Pierson, et al.
Published: (2018-02-01)

Tumor therapeutics in the era of “RECIST”: past, current insights, and future prospects
by: Zhilong Xu, et al.
Published: (2024-10-01)

RECIST and beyond
by: E Coche
Published: (2013-05-01)

Can we predict discordant RECIST 1.1 evaluations in double read clinical trials?
by: Hubert Beaumont, et al.
Published: (2023-10-01)

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
by: Christelle de La Fouchardière, et al.
Published: (2020-10-01)

Assessing immunotherapy response: going beyond RECIST by integrating early tumor growth kinetics
by: Mehdi Felfli, et al.
Published: (2024-12-01)

How Using Dedicated Software Can Improve RECIST Readings
by: Amandine René, et al.
Published: (2014-09-01)

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
by: Colleen M. Costelloe, Hubert H. Chuang, John E. Madewell, Naoto T. Ueno
Published: (2010-01-01)

The Prognostic Value of Total Tumor Volume Response Compared With RECIST1.1 in Patients With Initially Unresectable Colorectal Liver Metastases Undergoing Systemic Treatment
by: Nina J. Wesdorp, MD, et al.
Published: (2021-12-01)

Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria?
by: Valentina Magri, et al.
Published: (2024-02-01)

Accurate and Reproducible Application of the RECIST Criteria in CT Reporting in Oncology: A Learning Module
by: Nancy McNulty, et al.
Published: (2010-06-01)

Tumor size measurements of pancreatic cancer with neoadjuvant therapy based on RECIST guidelines: is MRI as effective as CT?
by: Panpan Yang, et al.
Published: (2023-01-01)

Automatic segmentation of hepatic metastases on DWI images based on a deep learning method: assessment of tumor treatment response according to the RECIST 1.1 criteria
by: Xiang Liu, et al.
Published: (2022-12-01)

Circulating cell-free DNA as predictor of pathological complete response in locally advanced rectal cancer patients undergoing preoperative chemoradiotherapy
by: Christina Glismand Truelsen, et al.
Published: (2022-09-01)

Tumor circulating biomarkers in colorectal cancer
by: Raana Bagheri, et al.
Published: (2024-01-01)

mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization
by: Hippocrates Moschouris, et al.
Published: (2014-03-01)

Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications
by: Claudia Parisi, et al.
Published: (2023-09-01)

INVITATION TO PARTICIPATE IN SYMPOSIUM ON RECIST AND BEYOND
by: MPRC, Pusat Media & Perhubungan Awam
Published: (2016)

Concordance between the tumor mutational status and circulating tumor DNA in patients with colorectal cancer
by: E. M. Polyanskaya, et al.
Published: (2022-04-01)

Circulating Tumor Cells as Predictive and Prognostic Biomarkers in Solid Tumors
by: Maurizio Capuozzo, et al.
Published: (2023-11-01)

Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer
by: Alessia Cimadamore, et al.
Published: (2020-06-01)

Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients
by: Huu Thinh Nguyen, et al.
Published: (2022-12-01)

Cervical Cancer Genetic Profile through Circulating Tumor DNA: What Can We Learn from Blood?
by: Sevastiani Antonouli, et al.
Published: (2024-07-01)

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
by: Frifeldt Sanne K, et al.
Published: (2011-03-01)

Determination of the surface recistivity of a textile fabric
by: 8096 British Standards Institution
Published: (1984)

Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients
by: Hiu Ting Chan, et al.
Published: (2023-01-01)

A Detailed Overview About the Single-Cell Analyses of Solid Tumors Focusing on Colorectal Cancer
by: William J. Kothalawala, et al.
Published: (2022-07-01)

Application of Circulating Tumor DNA in Precision Diagnosis and Treatment of Colorectal Cancer
by: YANG Wentao, et al.
Published: (2024-03-01)

Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT
by: Kevin Zwirtz, et al.
Published: (2022-06-01)

CIRCULATING TUMOR CELLS: WHERE WE LEFT OFF?
by: I. Kryvoshlyk, et al.
Published: (2021-08-01)